Data on Allergan’s Rapastinel and NRX-1074 (AGN-241660) presented at the Society for …

DUBLIN, Nov. 4, 2015 /PRNewswire/ — Allergan plc. (NYSE: AGN), a leading global pharmaceutical company today announced that 6 poster presentations for two investigational medications Rapastinel (GLYX-13 and NRX-1074 were presented at the Society for Neuroscience (SfN) Annual Meeting in Chicago, October 17 – 21, 2015. Logo – http://photos.prnewswire.com/prnh/20150612/222796LOGOThe titles of the poster presentations were as follows:About rapastinel (GLYX-13) and NRX-1074 (AGN-241660)Rapastinel (GLYX-13) is an investigational intravenous formulation of a novel NMDA receptor partial agonist, which is being evaluated for adjunctive treatment of MDD, and has shown a rapid onset of antidepressant efficacy 1 day after a single dose in a Phase 2 clinical trial of patients with MDD who had an inadequate response to one or more antidepressants. No psychotomimetic or hallucinogenic side effects were observed with rapastinel. A series of Phase…


Link to Full Article: Data on Allergan’s Rapastinel and NRX-1074 (AGN-241660) presented at the Society for …